tazarotene
Trade name: tazorac
Approved
Jun 13, 1997
Tazarotene is a prodrug and a member of the acetylenic class of retinoids. Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. When treating acne tazarotene may be taken in conjunction with an oral antibiotic. Tazarotene has been shown in peer-reviewed double blinded studies to reduce: mottling and hyperpigmentation, sallowness, fine wrinkling and coarse wrinkling in sun damaged skin. Histological studies have shown that long term (greater than 1 year) use of Tazarotene is associated with a significant reduction in atypical melanocytes and keratocytes - cells considered to be precursors of skin cancer. Some studies have shown long term use of Tazarotene to be associated with increased collagen production and better organization of skin collagen bundles. Although the exact mechanism of tazarotene action is not known, studies have shown that the active form of the drug (tazarotenic acid) binds to all three members of the retinoic acid receptor (RAR) family: RARa, RARb, and RARg, but shows relative selectivity for RARb, and RARg and may modify gene expression. It also has affinity for RXR receptors. Tazarotene is used to treat psoriasis, acne and sun damaged skin (photodamage). Tazarotene is marketed as Tazorac, Avage, Zorac, and Fabior. — NCATS
Clinical trial activity
60 trials · 47 clinical orgs · 16 marketing orgs
Earliest trial started Mar 1, 2002 (NCT00145106)
Timeline
1990s
- Jun 13, 1997
Allergan — Earliest FDA Approval
- Jun 13, 1997
Allergan — NDA Organization
- Jun 13, 1997
Allergan — NDA Secondary Org
- Jun 13, 1997
SmithKline Beecham — NDA Secondary Org
2000s
- Sep 29, 2000
GlaxoSmithKline — NDA Secondary Org
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2009
Earliest Phase 3 Sponsor(trial)
2010s
- May 11, 2012
Mayne Pharma — NDA Secondary Org
- Apr 3, 2017
Taro Pharmaceuticals — Marketing Organization
- Apr 3, 2017
Sun Pharmaceuticals — Marketing Organization
- Dec 22, 2017
Cosette — Marketing Organization
- Dec 22, 2017
G & W Laboratories Inc. — Marketing Organization
- Dec 22, 2017
ACP Nimble — Marketing Organization
- Jan 28, 2019
Fougera — Marketing Organization
- Jan 28, 2019
Novartis — Marketing Organization
- Apr 25, 2019
Bausch Health Companies — Marketing Organization
- Apr 25, 2019
Bausch Health Companies — NDA Secondary Org
- Dec 18, 2019
Dow Pharmaceutical Sciences — Marketing Organization
2020s
- Mar 20, 2023
Solaris Pharma Corp — Marketing Organization
- Mar 20, 2023
Donaldson Company — Marketing Organization
- Apr 25, 2023
Padagis Us — Marketing Organization
Indications
Approved for
Studied for
- Acne Keloid · Phase 3
- Acne Vulgaris · Phase 4
- Coronary Artery Disease · Phase 4
- Dermatology · Phase 2
- Erythema · Phase 4
- Exanthema · Phase 2
- Inflammation · Phase 4
- Lymphoma, T-Cell, Cutaneous · Phase 1/Phase 2
- Nails · Phase 4
- Neoplasms · Phase 2
- Neoplastic Syndromes, Hereditary · Phase 2
- Pigmentation · Phase 4
- Psoriasis · Phase 4
- Skin Diseases · Phase 4
- Skin Neoplasms · Phase 2
- Warts · Phase 2
Mechanism of action
- Retinoic acid receptorAGONIST
Retinoic acid receptor agonist
- UnclearUnclear
Unclear unclear
Combination products
duobrii
Approval history
- approvedJun 13, 1997
Chemistry & pharmacology
SMILES
CCOC(=O)C1=CN=C(C=C1)C#CC2=CC=C3SCCC(C)(C)C3=C2- Mol. weight
- 351.462 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaTazarotene ↗
- NCATS81BDR9Y8PS ↗
- ChEMBLCHEMBL1657 ↗
Also known as
- 3-pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester
- agn 190168
- agn-190168
- agn-190168
- agn-190168
- agn-190168
- agn-190168
- avage
- avage
- ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
- fabior
- fabior
- fabior
- idp-123
- tazaroc
- tazarotene
- tazarotene
- tazarotene
- tazarotene
- tazarotene
- tazarotene
- tazarotene
- tazarotene
- tazarotene
- tazarotene
- tazarotene
- tazaroteno
- tazaroteno
- tazarotenum
- tazarotenum
- tazorac
- tazorac
- tazorac
- tazorac
- tazorac
- tazorac
- zorac
- zorac
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06042647 | Phase 4 | Jul 13, 2023 | Dermatology Consulting Services, High Point NC |
| NCT05872256 | Phase 4 | Jun 1, 2023 | Dermatology Consulting Services, High Point NC |
| NCT05555797 | Phase 4 | Oct 30, 2022 | Assiut University |
| NCT05608499 | Phase 3 | Oct 4, 2022 | Bausch Health Companies, Icahn School of Medicine at Mount Sinai |
| NCT06015152 | N/A | Aug 1, 2022 | Jinnah Postgraduate Medical Centre, University of Karachi |
| NCT05314127 | Phase 2 | Apr 15, 2022 | Zagazig University |
| NCT05203315 | Phase 3 | Jan 17, 2022 | Austin Institute for Clinical Research |
| NCT05282771 | Early Phase 1 (Phase 1) | Apr 16, 2021 | Catawba Clinical Research, Taro Pharmaceuticals |
| NCT05704114 | Phase 4 | Feb 1, 2021 | The Dermatology Institute of Boston |
| NCT04720105 | Phase 4 | Nov 19, 2020 | Bausch Health Companies, Icahn School of Medicine at Mount Sinai |
| NCT05573425 | Phase 2/Phase 3 (Phase 3) | Aug 22, 2020 | Jinnah Postgraduate Medical Centre |
| NCT04119102 | Phase 4 | Oct 1, 2019 | Bausch Health Companies, Windsor Dermatology |
| NCT04071756 | Phase 2 | Sep 30, 2019 | Bayer, Harvard University |
| NCT03988439 | Phase 4 | Jun 8, 2019 | Bausch Health Companies |
| NCT03599193 | Phase 2 | Oct 17, 2017 | Dr. Reddy's Laboratories |
| NCT03263624 | Phase 4 | Oct 1, 2017 | Assiut University |
| NCT03341910 | Phase 2 | Aug 21, 2017 | Dr. Reddy's Laboratories |
| NCT03290027 | Phase 3 | Jul 31, 2017 | Dr. Reddy's Laboratories |
| NCT03168334 | Phase 3 | Jul 11, 2017 | Bausch Health Companies |
| NCT03292640 | Phase 3 | Jul 6, 2017 | Dr. Reddy's Laboratories |
Organizations
Research & Development (47)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bausch Health Companies | For profit | 10 | 7 | 4 | 2015 |
| GlaxoSmithKline | For profit | 9 | 0 | 4 | 2008 |
| Stiefel Laboratories | For profit | 9 | 9 | 4 | 2008 |
| Allergan | For profit | 5 | 3 | 2 | 2002 |
| Dr. Reddy's Laboratories | For profit | 4 | 4 | 2 | 2017 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 3 | 3 | 2 | 2011 |
| Altman Dermatology Associates | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Assiut University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Bayer | For profit | 2 | 0 | 1 | 2008 |
| Catawba Clinical Research | For profit | 2 | 0 | 1 | 2014 |
| Dermatology Consulting Services, High Point NC | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Fougera | For profit | 2 | 2 | 1 | 2016 |
| Galderma | For profit | 2 | 2 | 2 | 2006 |
| G & W Laboratories Inc. | For profit | 2 | 2 | 1 | 2014 |
| Herbert Irving Comprehensive Cancer Center | Academic/Hospital | 2 | 0 | 1 | 2004 |
| Jinnah Postgraduate Medical Centre | Academic/Hospital | 2 | 2 | 2 | 2020 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2004 |
| Taro Pharmaceuticals | For profit | 2 | 2 | 1 | 2014 |
| University of California, San Francisco | Academic/Hospital | 2 | 2 | 1 | 2004 |
| University of Utah | Academic/Hospital | 2 | 2 | 1 | 2005 |
Marketing (19)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ACP Nimble | For profit | MKTG | Dec 22, 2017 |
| Allergan | For profit | NDA | Jun 13, 1997 |
| Allergan | For profit | NDA2 | Jun 13, 1997 |
| Bausch Health Companies | For profit | MKTG | Apr 25, 2019 |
| Bausch Health Companies | For profit | NDA2 | Apr 25, 2019 |
| Cosette | For profit | MKTG | Dec 22, 2017 |
| Donaldson Company | For profit | MKTG | Mar 20, 2023 |
| Dow Pharmaceutical Sciences | For profit | MKTG | Dec 18, 2019 |
| Fougera | For profit | MKTG | Jan 28, 2019 |
| G & W Laboratories Inc. | For profit | MKTG | Dec 22, 2017 |
| GlaxoSmithKline | For profit | NDA2 | Sep 29, 2000 |
| Mayne Pharma | For profit | NDA2 | May 11, 2012 |
| Novartis | For profit | MKTG | Jan 28, 2019 |
| Padagis Us | For profit | MKTG | Apr 25, 2023 |
| SmithKline Beecham | For profit | NDA2 | Jun 13, 1997 |
| Solaris Pharma Corp | For profit | MKTG | Mar 20, 2023 |
| Sun Pharmaceuticals | For profit | MKTG | Apr 3, 2017 |
| Taro Pharmaceuticals | For profit | MKTG | Apr 3, 2017 |
| Taro Pharmaceuticals | For profit | SYN | Apr 3, 2017 |